Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myeloma.
delayed-type hypersensitivity
desensitization
lenalidomide
multiple myeloma
rash
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
revised:
15
12
2022
received:
29
11
2022
accepted:
20
12
2022
pubmed:
25
12
2022
medline:
15
3
2023
entrez:
24
12
2022
Statut:
ppublish
Résumé
Lenalidomide is considered a standard of care in multiple myeloma (MM) Some MM patients will develop delayed hypersensitivity to lenalidomide, which can lead to treatment discontinuation. Desensitization to lenalidomide can help these patients to complete treatment courses. Here, we aimed to review lenalidomide-treated MM patients who developed delayed hypersensitivity-induced rash and were treated with desensitization. A retrospective analysis of medical files of MM patients, who were desensitized to lenalidomide due to delayed hypersensitivity rash. Patients were treated between 2018 and 2022 at Hadassah Medical Center, Jerusalem, Israel. Search of patients yielded 16 patients that underwent desensitization to lenalidomide within the study period. The desensitization protocol consisted of a slow, 3-week-long protocol with lenalidomide's target doses of 10, 15, and 25 mg/day. Of the 16 patients, 10 (62.5%) succeeded to complete the protocol and thus were able to complete lenalidomide treatment cycles. One patient with unsuccessful desensitization was subsequently treated with first-generation IMiD thalidomide, with no rash appearing. None of the patients that were treated with desensitization had severe immune-mediated or non-dermatological adverse reactions. Desensitization to lenalidomide is safe and effective. Discontinuation of lenalidomide in MM patients with delayed hypersensitivity and no contraindication to desensitization should be discouraged. Collaboration between hematologists and allergists is needed.
Substances chimiques
Lenalidomide
F0P408N6V4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
407-413Informations de copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.
Tinsley SM, Kurtin SE, Ridgeway JA. Practical management of lenalidomide-related rash. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S64-S69.
Yau P, Jimenez-Zepeda VH, Bailey K, et al. Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center. Leuk Lymphoma. 2019;60(13):3199-3203.
Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood. 2015;126(21):2366-2369.
Lee MJ, Wickner P, Fanning L, et al. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. Br J Haematol. 2014;167(1):127-131.
Nardone B, Wu S, Garden BC, West DP, Reich LM, Lacouture ME. Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis. Clin Lymphoma Myeloma Leuk. 2013;13(4):424-429.
Sugi T, Nishigami Y, Saigo H, et al. Analysis of risk factors for lenalidomide-associated skin rash in patients with multiple myeloma. Leuk Lymphoma. 2021;62(6):1405-1410.
Sviggum HP, Davis MD, Rajkumar SV, Dispenzieri A. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol. 2006;142(10):1298-1302.
Tal Y, Maoz Segal R, Langevitz P, Kivity S, Darnizki Z, Agmon-Levin N. Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience. Lupus. 2018;27(5):703-707.
Scherer K, Brockow K, Aberer W, et al. Desensitization in delayed drug hypersensitivity reactions-an EAACI position paper of the Drug Allergy Interest Group. Allergy. 2013;68(7):844-852.
Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: a 2022 practice parameter update. J Allergy Clin Immunol. 2022;150:1333-1393.
Greenberger PA. Drug allergy. Allergy Asthma Proc. 2019;40(6):474-479.
Demir S, Gelincik A, Coskun R, et al. A practical 16-day desensitization protocol in lenalidomide-induced non-immediate hypersensitivity reactions. Ann Allergy Asthma Immunol. 2019;123(4):394-397.
Sugi T, Mita M, Yasu T, et al. Simple desensitization protocol for multiple myeloma patients with lenalidomide-induced skin rash: case series. J Clin Pharm Ther. 2021;46(6):1792-1795.
Phillips J, Kujawa J, Davis-Lorton M, Hindenburg A. Successful desensitization in a patient with lenalidomide hypersensitivity. Am J Hematol. 2007;82(11):1030.
Seki JT, Banglawala S, Lentz EM, Reece DE. Desensitization to lenalidomide in a patient with relapsed multiple myeloma. Clin Lymphoma Myeloma Leuk. 2013;13(2):162-165.
Lazzarato I, Gonzalez-Munoz M, Heredia R, et al. Successful desensitization procedure to lenalidomide in a patient with delayed hypersensitivity confirmed with a positive LTT. Eur Ann Allergy Clin Immunol. 2020;52(5):235-237.
Kuo AM, Hassoun H, Shah U, et al. Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma. Leuk Lymphoma. 2022;63(9):2233-2237.